Figure 5.

Galectin-3-potentiated in vivo thrombosis potential is dependent on platelet Dectin-1. (A) After intravenous injection of 10 μg/kg recombinant Galectin-3 or vehicle (saline) into mice, FeCl₃-induced arterial thrombus formation was initiated, and the thrombus area was recorded. Representative image at different time points are shown. Statistical analysis of thrombosis assessed using time to first thrombus (>20 μm) and area of thrombus at 10 min (n = 10) are shown. Scale bar = 100 μm. (B) Whole blood from Galectin-3-treated wild-type mice showed accelerated thrombus formation over an immobilized collagen surface at a shear rate of 1000 s⁻¹, whereas whole blood from Galectin-3-treated Dectin-1^−/− mice did not. After intravenous injection of 10 μg/kg recombinant Galectin-3 or vehicle into mice, whole blood was fluorescently tagged with FITC-labelled anti-CD41 antibody and then perfused through fibrillar collagen-coated bioflux plates. Representative images at the indicated time points are presented. Scale bar = 100 μm. (C) Platelet-rich plasma from Galectin-3-treated wild-type mice presented increased platelet aggregation; whereas platelet-rich plasma from Galectin-3-treated Dectin-1^−/− mice did not. Representative results and summary data (see Supplementary material online, Figure S14) are presented from four experiments. Statistical analyses were performed using two-way ANOVA followed by Sidak's multiple comparisons test. NS, no significance; *P < 0.05; **P < 0.01.